Globus Medical this week announced it received FDA approval for its Reflect non-fusion scoliosis correction system for young patients.
The Audubon, Pennsylvania-based company designed Reflect to correct progressive scoliosis in young patients while preserving motion, maintaining stability and allowing for future modulated growth.
“Treating scoliosis in the growing spine presents challenges related to reduced spinal mobility,” said Dr. Juan Rodrigues-Olaverri, board-certified orthopedic surgeon and Director of Pediatric Spinal Deformity Surgery and Early Onset Scoliosis at NYU Langone. “Reflect is an exciting development for curve correction that preserves freedom of motion in these young patients, and employs their own remaining growth to help repair the spinal curvature without the need for fusion.”
Reflect uses a flexible, durable cord that harnesses the power of innate patient growth for correction. The flexible cord is tensioned on the convex side to control the curve and allows for growth on the concave side. The implants can be inserted during a minimally invasive approach through a few small incisions between the ribs.
“Reflect has been available internationally for several years, and Globus Medical is very excited to make this system available to patients in the United States. This innovative solution highlights our commitment to addressing the clinical needs of the growing spine and improving the quality of life in these children. It is the latest advancement in scoliosis treatment that provides a non-fusion option for patients and their parents, as they consider the best treatment plan for their lifestyle and goals,” said Kelly Baker, Globus Medical senior VP of regulatory and clinical affairs.
